Skip to main content

People in the News: Geert Nygaard, Thomas Taapken, Uwe Staub

Premium

Epigenomics CEO Geert Nygaard has left the firm and Thomas Taapken has been appointed as sole member of the company's executive board, effective Oct. 1.

Taapken previously served as CFO at Epigenomics, a position he held since April 2011. He joined Epigenomics from Biotie Therapies in Finland, where he also served as CFO. He was appointed to this position in 2008, following a merger between Biotie Therapies and Elbion, where Taapken had been CFO since 2005. He has also held positions as an investment partner at Deutsche Venture Capital and Burrill & Company. Taapken also worked several years at Sanofi-Aventis.

Epigenomics has also promoted Uwe Staub, former senior vice president of research and development, to the position of COO.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.